| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | WAI YUEN TONG (00897): LETTER TO NON-REGISTERED SHAREHOLDER(S) AND REQUEST FORM | - | HKEx | ||
| 20.08. | WAI YUEN TONG (00897): LETTER TO EXISTING REGISTERED SHAREHOLDER(S) AND CHANGE REQUEST FORM | 4 | HKEx | ||
| 20.08. | WAI YUEN TONG (00897): MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE TARGET COMPANY | 1 | HKEx | ||
| 19.08. | WAI YUEN TONG (00897): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 19 AUGUST 2026 | 1 | HKEx | ||
| WAI YUEN TONG MEDICINE Aktie jetzt für 0€ handeln | |||||
| 31.07. | WAI YUEN TONG (00897): DELAY IN DESPATCH OF CIRCULAR AND GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES | 1 | HKEx | ||
| 24.07. | WAI YUEN TONG (00897): LETTER TO NON-REGISTERED HOLDER(S) AND REQUEST FORM | 1 | HKEx | ||
| 24.07. | WAI YUEN TONG (00897): LETTER TO EXISTING REGISTERED SHAREHOLDER(S) AND CHANGE REQUEST FORM | 2 | HKEx | ||
| 24.07. | WAI YUEN TONG (00897): FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 19 AUGUST 2026 | - | HKEx | ||
| 24.07. | WAI YUEN TONG (00897): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.07. | WAI YUEN TONG (00897): PROPOSALS FORTHE GRANT OF GENERAL MANDATES TO ISSUE AND TO REPURCHASE SHARES, RE-ELECTION OF THE RETIRING DIRECTORS, RE-APPOINTMENT ... | 1 | HKEx | ||
| 24.07. | WAI YUEN TONG (00897): 2026 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 5 | HKEx | ||
| 24.07. | WAI YUEN TONG (00897): 2026 ANNUAL REPORT | - | HKEx | ||
| 21.07. | WAI YUEN TONG (00897): CHANGE OF ADDRESS OF REGISTERED OFFICE IN BERMUDA | - | HKEx | ||
| 16.07. | WAI YUEN TONG (00897): JOINT ANNOUNCEMENT MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE TARGET COMPANY | - | HKEx | ||
| 10.07. | WAI YUEN TONG (00897): PROPOSED SHARE PREMIUM REDUCTION | 1 | HKEx | ||
| 25.06. | WAI YUEN TONG (00897): ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2026 | 2 | HKEx | ||
| 11.06. | WAI YUEN TONG (00897): NOTIFICATION OF BOARD MEETING | 1 | HKEx | ||
| 23.04. | WAI YUEN TONG (00897): NEXT DAY DISCLOSURE RETURN | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 43,770 | +2,77 % | Bayer, MustGrow Biologics, BASF zwischen Pflanzenschutz von gestern und Biologicals von morgen | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Große Agrarkonzerne bauen sich um und schauen dabei auf kleine Spezialisten. Am 2. September stellte Bayer Investoren seine Ziele... ► Artikel lesen | |
| MERCK KGAA | 137,85 | +1,58 % | Wer hat die Formel für die Abnehmspritze 2.0? Überholen BioNxt Solutions und Merck jetzt Novo Nordisk und Eli Lilly? Was macht BioNTech? | Der Boom bei Medikamenten gegen Übergewicht schafft innerhalb der Pharmabranche einen Milliardenmarkt mit einem Volumen von 100 Mrd. USD jährlich. Novo Nordisk und Eli Lilly kämpfen hier um die Vorherrschaft.... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 41,065 | 0,00 % | XFRA TEVA: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILTEVA PHARMACEUT.... ► Artikel lesen | |
| NOVO NORDISK | 34,420 | +1,34 % | Novo Nordisk zahlt bis zu 2,6 Milliarden Dollar für Biotech - warum Eli Lilly, GSK und AstraZeneca ebenfalls Milliarden auf neue Technologien setzen | ||
| LB PHARMACEUTICALS | 37,220 | +7,54 % | Needham initiates LB Pharmaceuticals stock with buy rating | ||
| GENERATE BIOMEDICINES | 14,340 | +2,50 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| PFIZER | 25,215 | +1,57 % | UBS stuft PFIZER INC auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Pfizer mit einem Kursziel von 27 US-Dollar auf "Neutral" belassen. Die Studiendaten von Tilrekimig gegen Atopische Dermatitis... ► Artikel lesen | |
| ZHENGYE BIOTECHNOLOGY | 1,730 | 0,00 % | Morning Market Movers: Zhengye Biotechnology, Lisata Therapeutics, Meiwu Technology, Danaher Corporation See Big Swings | WASHINGTON (dpa-AFX) - At 9:00 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SCHOTT PHARMA | 23,500 | -4,67 % | AKTIEN IM FOKUS: Aktien aus Diagnostik- und Laborbranche gesucht | FRANKFURT (dpa-AFX) - Aktien aus dem Segment Wirkstoffforschung, Diagnostik und Laborausrüstung haben am Dienstag auf den Kauflisten von Anlegern gestanden. Den Dax führten die Papiere von Qiagen und... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 55,20 | +0,91 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| KARDIGAN | 14,670 | +3,53 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| GSK | 20,710 | +1,02 % | GSK commits $800M to R&D, manufacturing hub, as Pennsylvania bonds deepen | ||
| AQUESTIVE THERAPEUTICS | 4,780 | +0,42 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm (dibutepinephrine) Sublingual Film | Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable... ► Artikel lesen | |
| OMNIAB | 4,790 | 0,00 % | StoneX raises OmniAb stock price target to $6 on new products | ||
| GILEAD SCIENCES | 134,82 | +2,79 % | Exklusiv: Gilead Sciences plant HSV-Weltpremiere am 24. Oktober | Am 24. Oktober könnte Gilead auf der IDWeek 2026 in Washington erstmals zeigen, wie groß man das HSV-Geschäft tatsächlich denkt. Nach exklusiven sharedeals.de-Informationen plant Gilead an diesem Tag... ► Artikel lesen |